The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies
Open accessAbstract
Background: Drug-coated balloons (DCBs) are a predominant revascularization therapy for symptomatic femoropopliteal artery disease. Because of the differences in excipients, paclitaxel dose, and coating morphologies, varying clinical outcomes have been observed with different DCBs. We report the results of 2 studies investigating the pharmacokinetic and clinical outcomes of a new DCB to treat femoropopliteal disease. Methods: In the ILLUMENATE Pivotal Study (Prospective, Randomized, Single-Blind, U.S. Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions With A Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300 symptomatic patients (Rutherford class 2–4) were randomly assigned to DCB (n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100). The primary safety end point was freedom from device- and procedure-related death through 30 days, and freedom from target limb major amputation and clinically driven target lesion revascularization through 12 months. The primary effectiveness end point was primary patency through 12 months. In the ILLUMENATE PK study (Pharmacokinetic Study of the Stellarex Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations were measured after last DCB deployment and at prespecified times (at 1, 4, 24 hours and at 7 and 14 days postprocedure) until no longer detectable. Results: In the ILLUMENATE Pivotal Study, baseline characteristics were similar between groups: 50% had diabetes mellitus, 41% were women, mean lesion length was 8.3 cm, and 44% were severely calcified. The primary safety end point was met (92.1% for DCB versus 83.2% for PTA, P =0.025 for superiority) and the primary patency rate was significantly higher with DCB (76.3% for DCB versus 57.6% for PTA, P =0.003). Primary patency per Kaplan-Meier estimates at day 365 was 82.3% for DCB versus 70.9% for PTA ( P =0.002). The rate of clinically driven target lesion revascularization was significantly lower in the DCB cohort (7.9% versus 16.8%, P =0.023). Improvements in ankle-brachial index, Rutherford class, and quality of life were comparable, but the PTA cohort required twice as many revascularizations. Pharmacokinetic outcomes showed that all patients had detectable paclitaxel levels after DCB deployment that declined within the first hour (54.4±116.9 ng/mL to 1.4±1.0 ng/mL). Conclusions: The data demonstrate superior safety and effectiveness of the Stellarex DCB in comparison with PTA, and plasma levels of paclitaxel fall to low levels within 1 hour. Clinical Trial Registration: URL: http://clinicaltrials.gov . Unique identifiers: NCT01858428 and NCT01912937.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Self-citationEpidemiology of Peripheral Artery Disease
Criqui, M. H., & Aboyans, V. (2015) · Circulation Research · doi:10.1161/circresaha.116.303849 · Cited by 1,785
Cited by
Katsanos, K., Spiliopoulos, S., Kitrou, P., Krokidis, M., & Karnabatidis, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011245 · Cited by 1,020
Criqui, M. H., Matsushita, K., Aboyans, V., Hess, C. N., Hicks, C. W., Kwan, T. W., McDermott, M. M., Misra, S., Ujueta, F., & on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, T. A. V. B. C. O. C. R. A. I. C. O. L. A. C. H. C. O. P. V. D. A. S. C. (2021) · Circulation · doi:10.1161/cir.0000000000001005 · Cited by 809
Gray, W. A., Keirse, K., Soga, Y., Benko, A., Babaev, A., Yokoi, Y., Schroeder, H., Prem, J. T., Holden, A., Popma, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32262-1 · Cited by 300
Self-citation
Metadata
- Authors
- Krishnan, P., Faries, P., Niazi, K., Jain, A., Sachar, R., Bachinsky, W. B., Cardenas, J., Werner, M., Brodmann, M., Mustapha, J. A., Mena-Hurtado, C., Jaff, M. R., Holden, A. H., Lyden, S. P., Mewissen, M., Katzen, B., Nanjundappa, A., Khuddus, M. A., Ricci, J., Fry, D., Shishehbor, M., Bosarge, C., Kovach, R., Goodwin, M., Raja, M. L., Mayeda, G., Sandhu, J., Rosales, O., Crowder, W., Paolini, D., Henretta, J., Desai, P., Farhat, N., Kang, E., Ansel, G., Ghani, M., Miller, W., Pollock, C., Korngold, E., Angle, J. F., Schultz, G., Gensler, T., Lopez, L., Park, J., Al-Khoury, G., Joels, C., & Metzger, C.
- Venue
- Circulation
- Published
- 2017-09-19
- Volume
- 136
- Issue
- 12
- Pages
- 1102-1113
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2739447339
- Cited by
- 217
- References
- 2
- FWCI
- 24.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.